Agenus Reports 72% Of Patients With Locally Advanced Dmmr Colon Cancer Had No Cancer Remaining At Surgery Following Six Weeks Of Bot+Bal In Phase 2 Neoasis Study At Esmo 2026
Agenus Inc AGEN.O:
AGENUS REPORTS 72% OF PATIENTS WITH LOCALLY ADVANCED DMMR COLON CANCER HAD NO CANCER REMAINING AT SURGERY FOLLOWING SIX WEEKS OF BOT+BAL IN PHASE 2 NEOASIS STUDY AT ESMO 2026
Further company coverage: AGEN.O